Macular telangiectasia type 2

Progress in Retinal and Eye Research

Volumn 34, Issue , 2013, Pages 49-77

  Charbel Issa, Peter ^a   Gillies, Mark C ^b   Chew, Emily Y ^c   Bird, Alan C ^d   Heeren, Tjebo F C ^a   Peto, Tunde ^d   Holz, Frank G ^a   Scholl, Hendrik P N ^e  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NATIONAL EYE INSTITUTE   (United States)

^d MOORFIELDS EYE HOSPITAL   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Imaging; Macular pigment; Macular telangiectasia; M ller cell; Neurodegeneration; Optical coherence tomography (OCT); Phenotype; Retina; Treatment; Vascular endothelial growth factor (VEGF)

Indexed keywords

ANECORTAVE; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

AUTOFLUORESCENCE IMAGING; BIOMICROSCOPY; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; ELECTROPHYSIOLOGY; FLUORESCENCE ANGIOGRAPHY; HUMAN; MACULAR TELANGIECTASIA TYPE 2; METAMORPHOSIS; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PHOTORECEPTOR; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA; REVIEW; TELANGIECTASIA; VISION; VISUAL ACUITY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MACULA LUTEA; RETINAL DISEASES; TELANGIECTASIS; VISUAL ACUITY;

EID: 84876713679     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2012.11.002     Document Type: Review

References (207)

1. Ablonczy Z., Crosson C.E. VEGF modulation of retinal pigment epithelium resistance. Exp. Eye Res. 2007, 85:762-771.
2. Abujamra S., Bonanomi M.T., Cresta F.B., Machado C.G., Pimentel S.L., Caramelli C.B. Idiopathic juxtafoveolar retinal telangiectasis: clinical pattern in 19 cases. Ophthalmologica 2000, 214:406-411.
3. Albini T.A., Benz M.S., Coffee R.E., Westfall A.C., Lakhanpal R.R., McPherson A.R., Holz E.R. Optical coherence tomography of idiopathic juxtafoveolar telangiectasia. Ophthalmic Surg. Lasers Imaging 2006, 37:120-128.
4. Alldredge C.D., Garretson B.R. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003, 23:113-116.
5. Arevalo J.F., Sanchez J.G., Garcia R.A., Wu L., Berrocal M.H., Rodriguez F.J., Rodriguez A., Novoa L.A., Garcia-Amaris R. Indocyanine-green-mediated photothrombosis (IMP) with intravitreal triamcinolone acetonide for macular edema secondary to group 2A idiopathic parafoveal telangiectasis without choroidal neovascularization: a pilot study. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:1673-1680.
6. Aung K.Z., Wickremasinghe S.S., Makeyeva G., Robman L., Guymer R.H. The prevalence estimates of macular telangiectasia Type 2: the Melbourne Collaborative Cohort Study. Retina 2010, 30:473-478.
7. Bakke E.F., Drolsum L. Iris microhaemangiomas and idiopathic juxtafoveolar retinal telangiectasis. Acta Ophthalmol. Scand. 2006, 84:818-822.
8. Barthelmes D., Gillies M.C., Fleischhauer J.C., Sutter F.K. A case of idiopathic perifoveal telangiectasia preceded by features of cone dystrophy. Eye 2007, 21:1534-1535.
9. Barthelmes D., Gillies M.C., Sutter F.K. Quantitative OCT analysis of idiopathic perifoveal telangiectasia. Invest. Ophthalmol. Vis. Sci. 2008, 49:2156-2162.
10. Barthelmes D., Sutter F.K., Gillies M.C. Differential optical densities of intraretinal spaces. Invest. Ophthalmol. Vis. Sci. 2008, 49:3529-3534.
11. Baumüller S., Charbel Issa P., Scholl H.P., Schmitz-Valckenberg S., Holz F.G. Outer retinal hyperreflective spots on spectral-domain optical coherence tomography in macular telangiectasia type 2. Ophthalmology 2010, 117:2162-2168.
12. Berger A.S., McCuen B.W., Brown G.C., Brownlow R.L. Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 1997, 17:94-98.
13. Bhosale P., Larson A.J., Frederick J.M., Southwick K., Thulin C.D., Bernstein P.S. Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) as a zeaxanthin-binding protein in the macula of the human eye. J. Biol. Chem. 2004, 279:49447-49454.
14. Bhosale P., Li B., Sharifzadeh M., Gellermann W., Frederick J.M., Tsuchida K., Bernstein P.S. Purification and partial characterization of a lutein-binding protein from human retina. Biochemistry 2009, 48:4798-4807.
15. Bok D., Yasumura D., Matthes M.T., Ruiz A., Duncan J.L., Chappelow A.V., Zolutukhin S., Hauswirth W., LaVail M.M. Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp. Eye Res. 2002, 74:719-735.
16. Bottoni F., Eandi C.M., Pedenovi S., Staurenghi G. Integrated clinical evaluation of type 2a idiopathic juxtafoveolar retinal telangiectasis. Retina 2010, 30:317-326.
17. Bringmann A., Pannicke T., Grosche J., Francke M., Wiedemann P., Skatchkov S.N., Osborne N.N., Reichenbach A. Muller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 2006, 25:397-424.
18. Bringmann A., Iandiev I., Pannicke T., Wurm A., Hollborn M., Wiedemann P., Osborne N.N., Reichenbach A. Cellular signaling and factors involved in Müller cell gliosis: neuroprotective and detrimental effects. Prog. Retin. Eye Res. 2009, 28:423-451.
19. Bruè C., Tseng J.J., Barbazetto I., Lima L.H., Yannuzzi L.A. Peculiar manifestation of macular telangiectasia type 2. Retin. Cases Brief Rep. 2011, 5:309-312.
20. Cahill M., O'Keefe M., Acheson R., Mulvihill A., Wallace D., Mooney D. Classification of the spectrum of Coats' disease as subtypes of idiopathic retinal telangiectasis with exudation. Acta Ophthalmol. Scand. 2001, 79:596-602.
21. Cakir M., Kapran Z., Basar D., Utine C.A., Eroglu F., Perente I. Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis. Eur. J. Ophthalmol. 2006, 16:711-717.
22. Casswell A.G., Chaine G., Rush P., Bird A.C. Paramacular telangiectasis. Trans. Ophthalmol. Soc. U.K. 1986, 105(Pt 6):683-692.
23. Cayouette M., Gravel C. Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum. Gene Ther. 1997, 8:423-430.
24. Cayouette M., Behn D., Sendtner M., Lachapelle P., Gravel C. Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J. Neurosci. 1998, 18:9282-9293.
25. Charbel Issa P., Helb H.M., Rohrschneider K., Holz F.G., Scholl H.P.N. Microperimetric assessment of patients with type II macular telangiectasia. Invest. Ophthalmol. Vis. Sci. 2007, 48:3788-3795.
26. Charbel Issa P., Holz F.G., Scholl H.P.N. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007, 114:1736-1742.
27. Charbel Issa P., Scholl H.P.N., Helb H.M., Holz F.G. Idiopathic macular telangiectasia. Medical Retina 2007, 183-197. Springer, Berlin, Heidelberg. F.G. Holz, R.F. Spaide (Eds.).
28. Charbel Issa P., Scholl H.P.N., Holz F.G. Intravitreal bevacizumab for the treatment of type 2 idiopathic macular telangiectasis. Retin. Cases Brief Rep. 2007, 1:189-191.
29. Charbel Issa P., Berendschot T.T., Staurenghi G., Holz F.G., Scholl H.P. Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia. Invest. Ophthalmol. Vis. Sci. 2008, 49:1172-1177.
30. Charbel Issa P., Finger R.P., Holz F.G., Helb H.M., Scholl H.P.N. A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging. Acta Ophthalmol. Scand. 2008, 86:464-465.
31. Charbel Issa P., Finger R.P., Holz F.G., Scholl H.P.N. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br. J. Ophthalmol. 2008, 92:941-945.
32. Charbel Issa P., Helb H.M., Holz F.G., Scholl H.P.N. Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia. Am. J. Ophthalmol. 2008, 245:169-175. on behalf of the MacTel Study, G.
33. Charbel Issa P., Holz F.G., Scholl H.P. The article by Kovach and Rosenfeld. Retina 2009, 29:717-718.
34. Charbel Issa P., Holz F.G., Scholl H.P.N. Metamorphopsia in patients with macular telangiectasia type 2. Doc. Ophthalmol. 2009, 119:133-140.
35. Charbel Issa P., Scholl H.P., Gaudric A., Massin P., Kreiger A.E., Schwartz S., Holz F.G. Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia. Eye 2009, 23:435-441.
36. Charbel Issa P., van der Veen R.L.P., Stifjs A., Holz F.G., Scholl H.P.N., Berendschot T.T.J.M. Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2. Exp. Eye Res. 2009, 89:25-31.
37. Charbel Issa P., Tröger E., Finger R., Holz F.G., Wilke R., Scholl H.P.N. Structure-function correlation of the human central retina. PLoS One 2010, 5:e12864.
38. Charbel Issa P., Finger R.P., Kruse K., Baumüller S., Scholl H.P., Holz F.G. Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am. J. Ophthalmol. 2011, 151:876-886.
39. Cherepanoff S., Killingsworth M.C., Zhu M., Nolan T., Hunyor A.P., Young S.H., Hageman G.S., Gillies M.C. Ultrastructural and clinical evidence of subretinal debris accumulation in type 2 macular telangiectasia. Br. J. Ophthalmol. 2012, 96(11):1404-1409.
40. Chew E.Y., Murphy R.P., Newsome D.A., Fine S.L. Parafoveal telangiectasis and diabetic retinopathy. Arch. Ophthalmol. 1986, 104:71-75.
41. Chong N.H.V., Alexander R.A., Waters L., Barnett K.C., Bird A.C., Luthert P.J. Repeated injections of a ciliary neurotrophic factor analogue leading to long-term photoreceptor survival in hereditary retinal degeneration. Invest. Ophthalmol. Vis. Sci. 1999, 40:1298-1305.
42. Chopdar A. Retinal telangiectasis in adults: fluorescein angiographic findings and treatment by argon laser. Br. J. Ophthalmol. 1978, 62:243-250.
43. Clemons T.E., Gillies M.C., Chew E.Y., Bird A.C., Peto T., Figueroa M., Harrington M.W. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. Invest. Ophthalmol. Vis. Sci. 2008, 49:4340-4346.
44. Clemons T.E., Gillies M.C., Chew E.Y., Bird A.C., Peto T., Figueroa M.J., Harrington M.W. Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiol. 2010, 17:66-73.
45. Costa R.A., Skaf M., Melo L.A., Calucci D., Cardillo J.A., Castro J.C., Huang D., Wojtkowski M. Retinal assessment using optical coherence tomography. Prog. Retin. Eye Res. 2006, 25:325-353.
46. Daicker B., Schiedt K., Adnet J.J., Bermond P. Canthaxanthin retinopathy. An investigation by light and electron microscopy and physicochemical analysis. Graefes Arch. Clin. Exp. Ophthalmol. 1987, 225:189-197.
47. Davidorf F.H., Pressman M.D., Chambers R.B. Juxtafoveal telangiectasis-a name change?. Retina 2004, 24:474-478.
48. Davies N.P., Morland A.B. Macular pigments: their characteristics and putative role. Prog. Retin. Eye Res. 2004, 23:533-559.
49. De Lahitte G.D., Cohen S.Y., Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am. J. Ophthalmol. 2004, 138:892-894.
50. Degli Esposti S., Egan C., Bunce C., Moreland J.D., Bird A., Robson A.G. Macular pigment parameters in patients with macular telangiectasia (MacTel) and normal subjects; implications of a novel analysis. Invest. Ophthalmol. Vis. Sci. 2012, 53:6568-6575.
51. Delaere L., Spielberg L., Leys A. Vertical transmission of macular telangiectasia type 2. Retin. Cases Brief Rep. 2011, 6:253-257.
52. Delori F.C., Dorey C.K., Staurenghi G., Arend O., Goger D.G., Weiter J.J. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest. Ophthalmol. Vis. Sci. 1995, 36:718-729.
53. Dorrell M.I., Aguilar E., Jacobson R., Yanes O., Gariano R., Heckenlively J., Banin E., Ramirez G.A., Gasmi M., Bird A., Siuzdak G., Friedlander M. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J. Clin. Invest. 2009, 119:611-623.
54. Drenser K., Sarraf D., Jain A., Small K.W. Crystalline retinopathies. Surv. Ophthalmol. 2006, 51:535-549.
55. Eandi C.M., Ober M.D., Freund K.B., Klais C.M., Slakter J.S., Sorenson J.A., Yannuzzi L.A. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Retina 2006, 26:780-785.
56. Eliassi-Rad B., Green W.R. Histopathologic study of presumed parafoveal telangiectasis. Retina 1999, 19:332-335.
57. Engelbrecht N.E., Aaberg T.M., Sung J., Lewis M.L. Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch. Ophthalmol. 2002, 120:320-324.
58. Finger R.P., Charbel Issa P., Fimmers R., Holz F.G., Rubin G.S., Scholl H.P.N. Reading performance is reduced due to parafoveal scotomas in patients with macular telangiectasia type 2. Invest. Ophthalmol. Vis. Sci. 2009, 50:1366-1370.
59. Fitzsimons R.B., Gurwin E.B., Bird A.C. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain 1987, 110(Pt 3):631-648.
60. Franze K., Grosche J., Skatchkov S.N., Schinkinger S., Foja C., Schild D., Uckermann O., Travis K., Reichenbach A., Guck J. Müller cells are living optical fibers in the vertebrate retina. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8287-8292.
61. Friedman S.M., Mames R.N., Stewart M.W. Subretinal hemorrhage after grid laser photocoagulation for idiopathic juxtafoveolar retinal telangiectasis. Ophthalmic Surg. 1993, 24:551-553.
62. Fuijkschot J., Cruysberg J.R., Willemsen M.A., Keunen J.E., Theelen T. Subclinical changes in the juvenile crystalline macular dystrophy in Sjogren-Larsson syndrome detected by optical coherence tomography. Ophthalmology 2008, 115:870-875.
63. Gamulescu M.A., Walter A., Sachs H., Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:1189-1193.
64. Gass J.D. A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal telangiectasis. Arch. Ophthalmol. 1968, 80:592-605.
65. Gass J.D.M. Stereoscopic Atlas of Macular Diseases 1977, Mosby, St. Louis. second ed.
66. Gass J.D., Blodi B.A. Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 1993, 100:1536-1546.
67. Gass J.D., Oyakawa R.T. Idiopathic juxtafoveolar retinal telangiectasis. Arch. Ophthalmol. 1982, 100:769-780.
68. Gaudric A., Ducos de L.G., Cohen S.Y., Massin P., Haouchine B. Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch. Ophthalmol. 2006, 124:1410-1419.
69. Gerrits H.J., Timmerman G.J. The filling-in process in patients with retinal scotomata. Vision Res. 1969, 9:439-442.
70. Gerth C., Zawadzki R.J., Werner J.S., Heon E. Retinal morphological changes of patients with X-linked retinoschisis evaluated by Fourier-domain optical coherence tomography. Arch. Ophthalmol. 2008, 126:807-811.
71. Gillies M.C., Zhu M., Chew E.Y., Barthelmes D., Hughes E., Ali H., Holz F.G., Scholl H.P.N., Charbel Issa P. Familial asymptomatic macular telangiectasia type 2. Ophthalmology 2009, 116:2422-2429.
72. Goralczyk R., Buser S., Bausch J., Bee W., Zuhlke U., Barker F.M. Occurrence of birefringent retinal inclusions in cynomolgus monkeys after high doses of canthaxanthin. Invest. Ophthalmol. Vis. Sci. 1997, 38:741-752.
73. Goralczyk R., Barker F.M., Buser S., Liechti H., Bausch J. Dose dependency of canthaxanthin crystals in monkey retina and spatial distribution of its metabolites. Invest. Ophthalmol. Vis. Sci. 2000, 41:1513-1522.
74. Green W.R., Quigley H.A., de la C.Z., Cohen B. Parafoveal retinal telangiectasis. Light and electron microscopy studies. Trans. Ophthalmol. Soc. U.K. 1980, 100:162-170.
75. Gregori N., Flynn H.W. Surgery for full-thickness macular hole in patients with idiopathic macular telangiectasia type 2. Ophthalmic Surg. Lasers Imaging 2010, 41 Online, 1-4.
76. Gregori N.Z., Berrocal A.M., Gregori G., Murray T.G., Knighton R.W., Flynn H.W., Dubovy S., Puliafito C.A., Rosenfeld P.J. Macular spectral-domain optical coherence tomography in patients with X linked retinoschisis. Br. J. Ophthalmol. 2009, 93:373-378.
77. Gualino V., Cohen S.Y., Delyfer M.N., Sahel J.A., Gaudric A. Optical coherence tomography findings in tamoxifen retinopathy. Am. J. Ophthalmol. 2005, 140:757-758.
78. Gurwin E.B., Fitzsimons R.B., Sehmi K.S., Bird A.C. Retinal telangiectasis in facioscapulohumeral muscular dystrophy with deafness. Arch. Ophthalmol. 1985, 103:1695-1700.
79. Hannan S.R., Madhusudhana K.C., Rennie C., Lotery A.J. Idiopathic juxtafoveolar retinal telangiectasis in monozygotic twins. Br. J. Ophthalmol. 2007, 91:1729-1730.
80. Heckenlively J.R., Hawes N.L., Friedlander M., Nusinowitz S., Hurd R., Davisson M., Chang B. Mouse model of subretinal neovascularization with choroidal anastomosis. Retina 2003, 23:518-522.
81. Helb H.M., Charbel Issa P., van der Veen R.L.P., Berendschot T.T.J.M., Scholl H.P.N., Holz F.G. Macular pigment density and distribution in patients with type II macular telangiectasia. Retina 2008, 28:808-816.
82. Hershberger V.S., Hutchins R.K., Laber P.W. Photodynamic therapy with verteporfin for subretinal neovascularization secondary to bilateral idiopathic acquired juxtafoveolar telangiectasis. Ophthalmic Surg. Lasers Imaging 2003, 34:318-320.
83. Hogan H., Alvarado J.A., Wedell J.E. Histology of the Human Eye: an Atlas and Textbook 1971, W.B. Saunders, Philadelphia.
84. Hussain N., Das T., Sumasri K., Ram L.S. Bilateral sequential photodynamic therapy for sub-retinal neovascularization with type 2A parafoveal telangiectasis. Am. J. Ophthalmol. 2005, 140:333-335.
85. Hutton W.L., Snyder W.B., Fuller D., Vaiser A. Focal parafoveal retinal telangiectasis. Arch. Ophthalmol. 1978, 96:1362-1367.
86. Isaacs T.W., McAllister I.L. Familial idiopathic juxtafoveolar retinal telangiectasis. Eye 1996, 10(Pt 5):639-642.
87. Jaissle G.B., May C.A., van de Pavert S.A., Wenzel A., Claes-May E., Giessl A., Szurman P., Wolfrum U., Wijnholds J., Fischer M.D., Humphries P., Seeliger M.W. Bone spicule pigment formation in retinitis pigmentosa: insights from a mouse model. Graefes Arch. Clin. Exp. Ophthalmol. 2010, 248:1063-1070.
88. Jonas J.B., Libondi T., von Baltz S., Beutelspacher S. Intravitreal bevacizumab for perifoveal telangiectasia. Acta Ophthalmol. 2011, 89:e607-e608.
89. Jorge R., Costa R.A., Calucci D., Scott I.U. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 245:1045-1048.
90. Karagiannis D., Georgalas I., Ladas I., Eustratios P., Mitropoulos P. A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis. Clin. Interv. Aging 2009, 4:63-65.
91. Kellner U., Kellner S. Klinik und Diagnostik der Zapfen-Dystrophien. Ophthalmologe 2009, 106:99-108.
92. Kiraly A., Nasemann J.E. Idiopathische juxtafoveoläre Telangiektasien. Langzeitverlauf des Sehvermögens. Ophthalmologe 1995, 92:698-703.
93. Klein R., Blodi B.A., Meuer S.M., Myers C.E., Chew E.Y., Klein B.E.K. The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study. Am. J. Ophthalmol. 2010, 150:55-62.
94. Koizumi H., Iida T., Maruko I. Morphologic features of group 2A idiopathic juxtafoveolar retinal telangiectasis in three-dimensional optical coherence tomography. Am. J. Ophthalmol. 2006, 142:340-343.
95. Koizumi H., Cooney M.J., Leys A., Spaide R.F. Centripetal retinal capillary proliferation in idiopathic parafoveolar telangiectasis. Br. J. Ophthalmol. 2007, 91:1719-1720.
96. Koizumi H., Slakter J.S., Spaide R.F. Full-thickness macular hole formation in idiopathic parafoveal telangiectasis. Retina 2007, 27:473-476.
97. Konstantinidis L., Mantel I., Zografos L., Ambresin A. Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:1567-1569.
98. Kovach J.L., Rosenfeld P.J. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 2009, 29:27-32.
99. Krivosic V., Tadayoni R., Massin P., Erginay A., Gaudric A. Spectral domain optical coherence tomography in type 2 idiopathic perifoveal telangiectasia. Ophthalmic Surg. Lasers Imaging 2009, 40:379-384.
100. Kurz-Levin M.M., Halfyard A.S., Bunce C., Bird A.C., Holder G.E. Clinical variations in assessment of bull's-eye maculopathy. Arch. Ophthalmol. 2002, 120:567-575.
101. Lai C.M., Dunlop S.A., May L.A., Gorbatov M., Brankov M., Shen W.Y., Binz N., Lai Y.K., Graham C.E., Barry C.J., Constable I.J., Beazley L.D., Rakoczy E.P. Generation of transgenic mice with mild and severe retinal neovascularisation. Br. J. Ophthalmol. 2005, 89:911-916.
102. Lamoureux E.L., Maxwell R.M., Marella M., Dirani M., Fenwick E., Guymer R.H. The longitudinal impact of macular telangiectasia (MacTel) type 2 on vision-related quality of life. Invest. Ophthalmol. Vis. Sci. 2011, 52:2520-2524.
103. LaVail M.M., Yasumura D., Matthes M.T., Lau-Villacorta C., Unoki K., Sung C.H., Steinberg R.H. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest. Ophthalmol. Vis. Sci. 1998, 39:592-602.
104. Lee B.L. Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis. Retina 1996, 16:344-346.
105. Lee H.C., Liu M., Ho A.C. Idiopathic juxtafoveal telangiectasis in association with celiac sprue. Arch. Ophthalmol. 2004, 122:411-413.
106. Lee S.W., Kim S.M., Kim Y.T., Kang S.W. Clinical features of idiopathic juxtafoveal telangiectasis in Koreans. Korean J. Ophthalmol. 2011, 25:225-230.
107. Len A.C., Powner M.B., Zhu L., Hageman G.S., Song X., Fruttiger M., Gillies M.C. Pilot application of iTRAQ to the retinal disease Macular Telangiectasia. J. Proteome Res. 2012, 11:537-553.
108. Leys A., Gilbert H.D., Van De S.W., Verougstraete C., Devriendt K., Lagae L., Gass J.D. Familial spastic paraplegia and maculopathy with juxtafoveolar retinal telangiectasis and subretinal neovascularization. Retina 2000, 20:184-189.
109. Li K.K., Goh T.Y., Parsons H., Chan W.M., Lam D.S. Use of intravitreal triamcinolone acetonide injection in unilateral idiopathic juxtafoveal telangiectasis. Clin. Experiment. Ophthalmol. 2005, 33:542-544.
110. Li B., Vachali P., Frederick J.M., Bernstein P.S. Identification of StARD3 as a lutein-binding protein in the macula of the primate retina. Biochemistry 2011, 50:2541-2549.
111. Liang F.Q., Aleman T.S., Dejneka N.S., Dudus L., Fisher K.J., Maguire A.M., Jacobson S.G., Bennett J. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol. Ther. 2001, 4:461-472.
112. Lira R.P., Silva V.B., Cavalcanti T.M., de Souza A.C., Pinto A.P. Intravitreous ranibizumab as treatment for macular telangiectasia type 2. Arch. Ophthalmol. 2010, 128:1075-1078.
113. Lowe M.A., Akduman L., Olk R.J. Laser photocoagulation and glucose metabolism in idiopathic juxtafoveolar retinal telangiectasis. Ophthalmic Surg. Lasers 1998, 29:126-139.
114. Maberley D.A., Yannuzzi L.A., Gitter K., Singerman L., Chew E., Freund K.B., Noguiera F., Sallas D., Willson R., Tillocco K. Radiation exposure: a new risk factor for idiopathic perifoveal telangiectasis. Ophthalmology 1999, 106:2248-2252.
115. MacDonald I.M., Sauve Y., Sieving P.A. Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants. Can. J. Ophthalmol. 2007, 42:399-402.
116. Maguluri S., Recchia C.C., Recchia F.M. Neurosensory macular detachment in group 2A juxtafoveolar telangiectasis and resolution following intravitreal triamcinolone. Retin. Cases Brief Rep. 2007, 1:20-21.
117. Mahajan V.B., Russell S.R., Stone E.M. A new macular dystrophy with anomalous vascular development, pigment spots, cystic spaces, and neovascularization. Arch. Ophthalmol. 2009, 127:1449-1457.
118. Maia Junior O.O., Takahashi W.Y., Bonanomi M.T., Nascimento V.P., Melo C.S. Injeção intravítrea de triancinolona no tratamento da telangiectasia retiniana justafoveolar idiopática. Arq. Bras. Oftalmol. 2006, 69:941-944.
119. Maia Junior O.O., Bonanomi M.T., Takahashi W.Y., Nascimento V.P., Takahashi B.S. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am. J. Ophthalmol. 2007, 144:296-299.
120. Mandal S., Venkatesh P., Abbas Z., Vohra R., Garg S. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:1825-1829.
121. Mansour A.M., Schachat A. Foveal avascular zone in idiopathic juxtafoveolar telangiectasia. Ophthalmologica 1993, 207:9-12.
122. Margalit E., Apte R.S., Sadda S.R. Idiopathic parafoveal telangiectasis associated with a foveal pseudovitelliform lesion. Br. J. Ophthalmol. 2002, 86:1455-1456.
123. Martinez J.A. Intravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasis. Arch. Ophthalmol. 2003, 121:1658-1659.
124. Maruko I., Iida T., Sekiryu T., Fujiwara T. Early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry. Br. J. Ophthalmol. 2008, 92:1488-1491.
125. Maruko I., Iida T., Sugano Y., Ojima A., Oyamada H., Sekiryu T. Demographic features of idiopathic macular telangiectasia in Japanese patients. Jpn. J. Ophthalmol. 2012, 56:152-158.
126. Matsumoto Y., Yuzawa M. Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn. J. Ophthalmol. 2010, 54:320-324.
127. Matsumoto C., Arimura E., Okuyama S., Takada S., Hashimoto S., Shimomura Y. Quantification of metamorphopsia in patients with epiretinal membranes. Invest. Ophthalmol. Vis. Sci. 2003, 44:4012-4016.
128. Matt G., Sacu S., Ahlers C., Schütze C., Dunavoelgyi R., Prager F., Prünte C., Schmidt-Erfurth U. Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye (Lond) 2010, 24:1535-1541.
129. Mauget-Faysse M., Gambrelle J., Quaranta-El M.M. Optical coherence tomography in tamoxifen retinopathy. Breast Cancer Res. Treat. 2006, 99:117-118.
130. Mavrakanas N., Mendrinos E., Pournaras C.J., Salzmann J. Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A. Acta Ophthalmol. 2009, 87:930-932.
131. Menchini U., Virgili G., Bandello F., Malara C., Rapizzi E., Lanzetta P. Bilateral juxtafoveolar telangiectasis in monozygotic twins. Am. J. Ophthalmol. 2000, 129:401-403.
132. Michaelides M., Chen L.L., Brantley M.A., Andorf J.L., Isaak E.M., Jenkins S.A., Holder G.E., Bird A.C., Stone E.M., Webster A.R. ABCA4 mutations and discordant ABCA4 alleles in patients and siblings with bull's-eye maculopathy. Br. J. Ophthalmol. 2007, 91:1650-1655.
133. Millay R.H., Klein M.L., Handelman I.L., Watzke R.C. Abnormal glucose metabolism and parafoveal telangiectasia. Am. J. Ophthalmol. 1986, 102:363-370.
134. Moisseiev J., Lewis H., Bartov E., Fine S.L., Murphy R.P. Superficial retinal refractile deposits in juxtafoveal telangiectasis. Am. J. Ophthalmol. 1990, 109:604-605.
135. Mondal S., Chattopadhyay A., Paul S. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to idiopathic macular telangiectasia. Bengal Ophthalmic J. 2010, 15-19.
136. Narayanan R., Chhablani J., Sinha M., Dave V., Tyagi M., Pappuru R.R., Kuppermann B.D. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina 2012, 32:2001-2005.
137. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S.J., Robinson G.S., Adamis A.P., Shima D.T. Vascular endothelial growth factor-a is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 2007, 171:53-67.
138. Nishimura M., Taniguchi Y. Retinal vascular patterns in the macula and the perimacular area in premature and full-term infants. Ophthalmologica 1982, 185:147-157.
139. Oh K.T., Park D.W. Bilateral juxtafoveal telangiectasis in a family. Retina 1999, 19:246-247.
140. Okamoto N., Tobe T., Hackett S.F., Ozaki H., Vinores M.A., LaRochelle W., Zack D.J., Campochiaro P.A. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am. J. Pathol. 1997, 151:281-291.
141. Olson J.L., Mandava N. Macular hole formation associated with idiopathic parafoveal telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:411-412.
142. Ooto S., Hangai M., Takayama K., Arakawa N., Tsujikawa A., Koizumi H., Oshima S., Yoshimura N. High-resolution photoreceptor imaging in idiopathic macular telangiectasia type 2 using adaptive optics scanning laser ophthalmoscopy. Invest. Ophthalmol. Vis. Sci. 2011, 52:5541-5550.
143. Park D., Schatz H., McDonald H.R., Johnson R.N. Fibrovascular tissue in bilateral juxtafoveal telangiectasis. Arch. Ophthalmol. 1996, 114:1092-1096.
144. Park D.W., Schatz H., McDonald H.R., Johnson R.N. Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 1997, 104:1838-1846.
145. Parmalee N.L., Schubert C., Merriam J.E., Allikmets K., Bird A.C., Gillies M.C., Peto T., Figueroa M., Friedlander M., Fruttiger M., Greenwood J., Moss S.E., Smith L.E., Toomes C., Inglehearn C.F., Allikmets R. Analysis of candidate genes for macular telangiectasia type 2. Mol. Vis. 2010, 16:2718-2726.
146. Parmalee N.L., Schubert C., Figueroa M., Bird A.C., Peto T., Gillies M.C., Bernstein P.S., Kiryluk K., Terwilliger J.D., Allikmets R. Identification of a potential susceptibility locus for macular telangiectasia type 2. PLoS One 2012, 7:e24268.
147. Parodi M.B., Iacono P., Ravalico G. Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 245:612-615.
148. Patel B., Duvall J., Tullo A.B. Lamellar macular hole associated with idiopathic juxtafoveolar telangiectasia. Br. J. Ophthalmol. 1988, 72:550-551.
149. Potter M.J., Szabo S.M., Chan E.Y., Morris A.H. Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am. J. Ophthalmol. 2002, 133:149-151.
150. Potter M.J., Szabo S.M., Sarraf D., Michels R., Schmidt-Erfurth U. Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. Can. J. Ophthalmol. 2006, 41:34-37.
151. Powner M.B., Gillies M.C., Tretiach M., Scott A., Guymer R.H., Hageman G.S., Fruttiger M. Perifoveal Müller cell depletion in a case of macular telangiectasia type 2. Ophthalmology 2010, 117:2407-2416.
152. Powner M.B., Scott A., Zhu M., Munro P.M., Foss A.J., Hageman G.S., Gillies M.C., Fruttiger M. Basement membrane changes in capillaries of the ageing human retina. Br. J. Ophthalmol. 2011, 95:1316-1322.
153. Querques G., Coscas G., Soubrane G., Souied E.H. Type II idiopathic macular telangiectasia and soft confluent drusen. Eur. J. Ophthalmol. 2010, 20:466-468.
154. Reese A. Telangiectasis of the retina and Coats' disease. Am. J. Ophthalmol. 1956, 42:1-8.
155. Rishi P., Shroff D., Rishi E. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:619-621.
156. Roller A.B., Folk J.C., Patel N.M., Boldt H.C., Russell S.R., Abramoff M.D., Mahajan V.B. Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 2011, 31:1848-1855.
157. Roorda A., Romero-Borja F., Donnelly Iii W., Queener H., Hebert T., Campbell M. Adaptive optics scanning laser ophthalmoscopy. Opt. Express 2002, 10:405-412.
158. Ruys J., De Laey J.J., Vanderhaeghen Y., Van Aken E.H. Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye (Lond) 2007, 21:1433-1434.
159. Saint-Geniez M., Maharaj A.S., Walshe T.E., Tucker B.A., Sekiyama E., Kurihara T., Darland D.C., Young M.J., D'Amore P.A. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS One 2008, 3:e3554.
160. Sallo F.B., Leung I., Chung M., Wolf-Schnurrbusch U.E., Dubra A., Williams D.R., Clemons T., Pauleikhoff D., Bird A.C., Peto T. Retinal crystals in type 2 idiopathic macular telangiectasia. Ophthalmology 2011, 118:2461-2467.
161. Sallo F.B., Leung I., Mathenge W., Kyari F., Kuper H., Gilbert C.E., Bird A.C., Peto T. The prevalence of type 2 idiopathic macular telangiectasia in two African populations. Ophthalmic Epidemiol. 2012, 19:185-189.
162. Sallo F.B., Peto T., Egan C., Wolf-Schnurrbusch U.E., Clemons T.E., Gillies M.C., Pauleikhoff D., Rubin G.S., Chew E.Y., Bird A.C. " En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. Invest. Ophthalmol. Vis. Sci. 2012, 53:6145-6152.
163. Sarraf D., Ceron O., Rasheed K., Drenser K.A., Casey R. West African crystalline maculopathy. Arch. Ophthalmol. 2003, 121:338-342.
164. Sawa M., Gomi F., Ueno C., Suzuki M., Nishida K. Comparison of macular pigment in three types of macular telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2012, [Epub ahead of print].
165. Schmitz-Valckenberg S., Fan K., Nugent A., Rubin G.S., Peto T., Tufail A., Egan C., Bird A.C., Fitzke F.W. Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia. Arch. Ophthalmol. 2008, 126:330-335.
166. Schmitz-Valckenberg S., Ong E.E., Rubin G.S., Peto T., Tufail A., Egan C.A., Bird A.C., Fitzke F.W. Structural and functional changes over time in MacTel patients. Retina 2009, 29:1314-1320.
167. Shanmugam M.P., Agarwal M. RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J. Ophthalmol. 2005, 53:61-63.
168. Shanmugam M.P., Mythri H.M., Shetty N.S. Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane. Indian J. Ophthalmol. 2007, 55:490-491.
169. Shen W., Zhang J., Chung S.H., Hu Y., Ma Z., Gillies M.C. Submacular DL-alpha-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature. Invest. Ophthalmol. Vis. Sci. 2011, 52:119-127.
170. Shen W., Fruttiger M., Zhu L., Chung S.H., Barnett N.L., Kirk J.K., Lee S., Coorey N.J., Killingsworth M., Sherman L.S., Gillies M.C. Conditional Müller Cell Ablation Causes Independent Neuronal and Vascular Pathologies in a Novel Transgenic Model. J. Neurosci. 2012, 32(45):15715-15727.
171. Shukla D. Evolution and management of macular hole secondary to type 2 idiopathic macular telangiectasia. Eye (Lond) 2012, 25:532-533.
172. Shukla D., Venkatesh R. Spontaneous closure of full-thickness macular hole in type 2 idiopathic macular telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2012, 250:1711-1712.
173. Shukla D., Singh J., Kolluru C.M., Kim R., Namperumalsamy P. Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. Am. J. Ophthalmol. 2004, 138:147-149.
174. Siddiqui N., Fekrat S. Group 2A idiopathic juxtafoveolar retinal telangiectasia in monozygotic twins. Am. J. Ophthalmol. 2005, 139:568-570.
175. Sieving P.A., Caruso R.C., Tao W., Coleman H.R., Thompson D.J., Fullmer K.R., Bush R.A. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3896-3901.
176. Sigler E.J., Randolph J.C., Calzada J.I., Charles S. Comparison of observation, intravitreal bevacizumab, or pars plana vitrectomy for non-proliferative type 2 idiopathic macular telangiectasia. Graefes Arch. Clin. Exp. Ophthalmol. 2012, [Epub ahead of print].
177. Smithen L.M., Spaide R.F. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am. J. Ophthalmol. 2004, 138:884-885.
178. Snodderly D.M., Auran J.D., Delori F.C. The macula pigment. II. Spatial distribution in primate retinas. Invest. Ophthalmol. Vis. Sci. 1984, 25:674-685.
179. Snodderly D.M., Brown P.K., Delori F.C., Auran J.D. The macular pigment. I. Absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest. Ophthalmol. Vis. Sci. 1984, 25:660-673.
180. Snyers B., Verougstraete C., Postelmans L., Leys A., Hykin P. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am. J. Ophthalmol. 2004, 137:812-819.
181. Stoffelns B.M., Schoepfer K., Kramann C. Idiopathische makuläre Teleangiektasie (IMT) - Verlaufsbeobachtung mit und ohne Laserphotokoagulation. Klin Monbl Augenheilkd 2010, 227:252-256.
182. Surguch V., Gamulescu M.A., Gabel V.P. Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 245:783-788.
183. Szental J.A., Baird P.N., Richardson A.J., Islam F.M., Scholl H.P., Charbel Issa P., Holz F.G., Gillies M., Guymer R.H. Analysis of glutathione S-transferase Pi isoform (GSTP1) single-nucleotide polymorphisms and macular telangiectasia type 2. Int. Ophthalmol. 2010, 30:645-650.
184. Takayama K., Ooto S., Tamura H., Yamashiro K., Otani A., Tsujikawa A., Yoshimura N. Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia. Eye (Lond) 2010, 24:1492-1497.
185. Takayama K., Ooto S., Tamura H., Yamashiro K., Otani A., Tsujikawa A., Yoshimura N. Retinal structural alterations and macular sensitivity in idiopathic macular telangiectasia type 1. Retina 2012, 32:1973-1980.
186. Tao W., Wen R., Goddard M.B., Sherman S.D., O'Rourke P.J., Stabila P.F., Bell W.J., Dean B.J., Kauper K.A., Budz V.A., Tsiaras W.G., Acland G.M., Pearce-Kelling S., Laties A.M., Aguirre G.D. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 2002, 43:3292-3298.
187. TAP-Study-Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalmol. 1999, 117:1329-1345.
188. Theelen T., Berendschot T.T., Boon C.J., Hoyng C.B., Klevering B.J. Analysis of visual pigment by fundus autofluorescence. Exp. Eye Res. 2008, 86:296-304.
189. Tikellis G., Gillies M.C., Guymer R.H., McAllister I.L., Shaw J.E., Wong T.Y. Retinal vascular caliber and macular telangiectasia type 2. Ophthalmology 2009, 116:319-323.
190. Tobe T., Okamoto N., Vinores M.A., Derevjanik N.L., Vinores S.A., Zack D.J., Campochiaro P.A. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest. Ophthalmol. Vis. Sci. 1998, 39:180-188.
191. Toy B.C., Koo E., Cukras C., Meyerle C.B., Chew E.Y., Wong W.T. Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intrevitreal ranibizumab: results of a phase 2 clinical trial. Retina 2012, 32:996-1006.
192. Trauzettel-Klosinski S. Reading disorders due to visual field defects: a neuro-ophthalmological view. Neuro-Ophthalmology 2002, 27:79-90.
193. Trieschmann M., van Kuijk F.J., Alexander R., Hermans P., Luthert P., Bird A.C., Pauleikhoff D. Macular pigment in the human retina: histological evaluation of localization and distribution. Eye 2008, 22:132-137.
194. van der Veen R.L., Fuijkschot J., Willemsen M.A., Cruysberg J.R., Berendschot T.T., Theelen T. Patients with Sjogren-Larsson syndrome lack macular pigment. Ophthalmology 2010, 117:966-971.
195. van Eeden P.E., Tee L.B., Lukehurst S., Lai C.M., Rakoczy E.P., Beazley L.D., Dunlop S.A. Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2006, 47:4638-4645.
196. Vianna R.N., Squeri G., Turquetti R., Brasil O.F., Burnier M.N. Intravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasis. Can. J. Ophthalmol. 2008, 43:492-493.
197. Watzke R.C., Klein M.L., Folk J.C., Farmer S.G., Munsen R.S., Champfer R.J., Sletten K.R. Long-term juxtafoveal retinal telangiectasia. Retina 2005, 25:727-735.
198. Weber B.H., Schrewe H., Molday L.L., Gehrig A., White K.L., Seeliger M.W., Jaissle G.B., Friedburg C., Tamm E., Molday R.S. Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6222-6227.
199. Whitehead A.J., Mares J.A., Danis R.P. Macular pigment: a review of current knowledge. Arch. Ophthalmol. 2006, 124:1038-1045.
200. Willemsen M.A., Cruysberg J.R., Rotteveel J.J., Aandekerk A.L., Van Domburg P.H., Deutman A.F. Juvenile macular dystrophy associated with deficient activity of fatty aldehyde dehydrogenase in Sjogren-Larsson syndrome. Am. J. Ophthalmol. 2000, 130:782-789.
201. Windisch R., Kozousek V. Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis. Can. J. Ophthalmol. 2008, 43:489-490.
202. Wong W.T., Forooghian F., Majumdar Z., Bonner R.F., Cunningham D., Chew E.Y. Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. Am. J. Ophthalmol. 2009, 148:573-583.
203. Wu L., Evans T., Arevalo J.F., Berrocal M.H., Rodriguez F.J., Hsu M., Sanchez J.G. Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia. Retina 2008, 28:314-319.
204. Yannuzzi L.A. The Retinal Atlas 2010, Saunders Elsevier.
205. Yannuzzi L.A., Bardal A.M., Freund K.B., Chen K.J., Eandi C.M., Blodi B. Idiopathic macular telangiectasia. Arch. Ophthalmol. 2006, 124:450-460.
206. Zeimer M.B., Kromer I., Spital G., Lommatzsch A., Pauleikhoff D. Macular telangiectasia: patterns of distribution of macular pigment and response to supplementation. Retina 2010, 30:1282-1293.
207. Zeimer M.B., Padge B., Heimes B., Pauleikhoff D. Idiopathic macular telangiectasia type 2: distribution of macular pigment and functional investigations. Retina 2010, 30:586-595.